Skip to content

    Research Use Only

    This site is an educational resource for research compounds. We do not endorse human consumption of any compound. BodyHackGuide and BHG Labs share common ownership; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.

    100K+ researchers trust BodyHackGuide — Join r/BodyHackGuide
    Metabolic & Weight LossPhase 3

    Cagrilintide Dosage Guide: Protocols, Calculator & Safety

    Everything you need to know about Cagrilintide dosing — protocols, safety, and where to buy.

    Frequency

    Once weekly

    Half-Life

    ~159 hours (approximately 7 days)

    Dosage Calculator

    Calculate exact dosing for Cagrilintide.

    Dosing Protocols

    Beginner

    Context: CagriSema is not yet FDA-approved (as of April 2026 — Phase 3 REDEFINE program complete, approval expected 2025-2026). This beginner protocol assumes either clinical trial enrollment, off-label compounded cagrilintide + semaglutide use, or early commercial availability.

    Preparation Phase (Weeks -2 to 0):

    • Confirm BMI ≥27 (with comorbidities) or ≥30 for obesity indication
    • Baseline labs: HbA1c, lipid panel, liver enzymes, TSH, testosterone (men), basic metabolic panel
    • Body composition baseline: DEXA scan (preferred) or impedance analysis
    • Medical history review: pancreatitis history, thyroid disease (MTC/MEN2 contraindicated), family history of thyroid cancer
    • Mental health screening: eating disorder history, depression
    • Weight history documentation
    • Discuss realistic expectations (20-22% weight loss at 68 weeks is the high end)

    Beginner Protocol (Weeks 1-16):

    CagriSema Initiation:

    • Week 1-4: Semaglutide 0.25 mg SC weekly + Cagrilintide 0.3 mg SC weekly
    • Week 5-8: Semaglutide 0.5 mg SC weekly + Cagrilintide 0.6 mg SC weekly
    • Week 9-12: Semaglutide 1.0 mg SC weekly + Cagrilintide 1.2 mg SC weekly
    • Week 13-16: Semaglutide 1.7 mg SC weekly + Cagrilintide 2.4 mg SC weekly
    • Week 17+: Semaglutide 2.4 mg + Cagrilintide 2.4 mg (full dose)

    Injection Timing:

    • Same day each week (typically Sunday or Monday)
    • Two separate injections (semaglutide and cagrilintide) — cannot be pre-mixed in same syringe
    • Can be same injection site area or different
    • Rotate sites to prevent irritation

    Administration:

    • Subcutaneous injection
    • Abdomen, thigh, or upper arm
    • 29-31G insulin syringes (5/16" or 1/2")
    • Clean site, inject slowly, brief pressure after
    • Dispose needle in sharps container

    Dietary Guidance:

    • Eat smaller portions — appetite will be significantly reduced
    • Prioritize protein: 1.6-2.0 g/kg ideal body weight to preserve lean mass
    • Adequate hydration: 2-3 L water daily
    • Moderate carbohydrate intake
    • Avoid late-night eating (gastric emptying already slowed)
    • Multivitamin supplementation

    Exercise Guidance:

    • Resistance training 2-3x weekly: preserve lean muscle mass during rapid weight loss
    • Compound movements: squats, deadlifts, presses, pulls
    • Progressive overload approach
    • Adequate recovery (weight loss is a stressor)
    • Cardiovascular: 150 min/week moderate OR 75 min/week vigorous

    Weeks 1-4 Expectations:

    • Initial GI side effects likely: nausea, appetite suppression, early satiety
    • Weight loss: typically 2-4% of body weight
    • Fatigue, especially with rapid weight loss
    • Mild dehydration risk

    Weeks 5-12 Expectations:

    • GI tolerance improves
    • Weight loss continues: typically 4-8% by week 12
    • Energy typically normalizes
    • Ongoing titration requires patience

    Week 16 Decision Points:

    • If full dose tolerated and weight loss on track: continue to intermediate protocol
    • If ongoing GI symptoms limiting dose: maintain current dose longer before escalating
    • If plateau: reassess calorie intake, exercise, adherence
    • If intolerable side effects: reduce dose or switch therapy

    Monitoring:

    • Weekly: body weight, blood pressure, subjective symptoms
    • Month 1: clinical check-in, adjust titration as needed
    • Month 3: comprehensive labs + body composition
    • Month 6: comprehensive labs + body composition + DEXA

    Red Flags Requiring Medical Attention:

    • Severe persistent nausea/vomiting with dehydration
    • Severe abdominal pain (pancreatitis concern)
    • Symptoms suggestive of gallbladder disease
    • Severe fatigue beyond expected
    • Mood changes or depression
    • Any signs of hypoglycemia (especially if diabetic)
    • Neck mass or thyroid-related symptoms

    What Beginner Protocol Does NOT Cover:

    • Maintenance dosing after initial 6-12 month weight loss phase
    • Management of weight regain after discontinuation
    • Pediatric use
    • Pregnancy (contraindicated)
    • Complex diabetic management (requires endocrinology co-management)
    Standard

    For users who have completed 16+ weeks of titration successfully and want to optimize long-term weight loss maintenance.

    Intermediate Protocol (Months 4-12):

    Full Maintenance Dose:

    • Semaglutide 2.4 mg SC weekly
    • Cagrilintide 2.4 mg SC weekly
    • Consistent weekly schedule
    • Most weight loss occurs in this phase

    Optimization Strategies:

    Protein Optimization:

    • 1.6-2.0 g/kg ideal body weight daily
    • Distribute across 3-4 meals (20-40 g per meal)
    • Leucine-rich sources preferred (dairy, meat, whey)
    • Consider whey protein supplementation if intake falls short

    Resistance Training Progression:

    • Progressive overload essential
    • 3-4 sessions weekly during stable dosing phase
    • Compound movements prioritized
    • Track strength metrics (not just weight)
    • Consider personal trainer or structured program

    Cardiovascular Exercise:

    • 150 minutes moderate-intensity OR 75 minutes vigorous weekly
    • HIIT 1-2x weekly for metabolic benefits
    • Walking for active recovery
    • Avoid overtraining (rest is part of program)

    Nutritional Quality:

    • Whole food emphasis
    • Adequate fiber (25-35 g daily)
    • Fatty fish 2x weekly for omega-3
    • Abundant vegetables for micronutrients
    • Limit ultra-processed foods

    Sleep Optimization:

    • 7-9 hours nightly
    • Consistent sleep/wake schedule
    • Appropriate sleep environment
    • Address sleep apnea if present (weight loss may improve)

    Stress Management:

    • Chronic stress impairs weight loss
    • Meditation, mindfulness, or therapy as appropriate
    • Social support for eating behavior changes
    • Address underlying emotional eating

    Hormonal Monitoring:

    Thyroid:

    • TSH, free T4 every 6 months
    • Weight loss may alter thyroid needs
    • Adjust replacement as needed

    HPG Axis:

    • Men: testosterone every 6 months during rapid weight loss
    • Women: menstrual tracking; if amenorrhea develops, consult reproductive endocrinology
    • Significant weight loss can suppress HPG axis via leptin reduction

    Metabolic Markers:

    • HbA1c every 3-6 months
    • Lipid panel every 3-6 months
    • Liver enzymes quarterly initially
    • Kidney function annually

    Body Composition:

    • DEXA every 6 months (gold standard)
    • Track lean mass, fat mass, visceral adipose tissue
    • Target: preserve or minimize lean mass loss during weight loss
    • Redistribute if lean mass dropping excessively (increase protein, resistance training)

    Common Intermediate Phase Issues:

    Plateau (months 6-9):

    • Expected for most patients around 40-50% of total expected weight loss
    • Reassess caloric intake (may need adjustment)
    • Reassess activity levels
    • Check adherence to injections
    • Consider adding resistance training if not already

    Decreased Appetite Extremes:

    • If inadequate caloric intake threatens lean mass: prioritize protein
    • Structured meal timing despite low hunger
    • Consider temporary dose reduction if severe

    Lean Mass Loss:

    • Monitor via DEXA
    • Intervene: increase protein, intensify resistance training
    • Consider GH peptides (Sermorelin, CJC-1295/Ipamorelin) if significant
    • Slow rate of weight loss if needed

    Expected Trajectory:

    • Month 6: 10-15% weight loss typical
    • Month 9: 15-20% weight loss typical
    • Month 12: 18-22% weight loss typical (matches REDEFINE 1 landmark cohort)
    • Month 18: plateau approaches typical nadir

    Side Effect Management:

    Persistent GI Issues:

    • Usually improve with time
    • Split injection or timing changes don't affect weekly drugs
    • Ondansetron for persistent nausea (physician guidance)
    • Eat smaller, more frequent meals

    Fatigue:

    • Ensure adequate calories (not excessive deficit)
    • Adequate sleep
    • Iron studies if persistent
    • Thyroid status check

    Hair Loss:

    • Common during rapid weight loss
    • Usually resolves when weight stabilizes
    • Adequate protein, zinc, biotin
    • Genetics a factor

    Quality of Life Monitoring:

    • Energy levels
    • Mood and mental health
    • Social eating situations
    • Body image (positive and negative)
    • Sleep quality
    • Sexual function

    Partner/Family Support:

    • Education on weight-loss drugs
    • Eating pattern changes
    • Support for new lifestyle
    • Joint meal planning

    When to Consider Transition:

    Progress to Advanced Protocol:

    • After 12-18 months of successful weight loss
    • Stable lifestyle habits established
    • Addressing long-term maintenance

    Modify Approach:

    • If progress stalls >3 months
    • If side effects become intolerable
    • If complex medical issues develop

    Reduce Dose:

    • After reaching target weight
    • If lean mass loss excessive
    • Part of maintenance planning

    Discontinue:

    • Target weight achieved with stable lifestyle
    • Medical necessity
    • Insurance coverage issues
    • Personal choice
    • Always with maintenance plan to prevent regain
    Advanced

    For experienced users approaching or maintaining target weight, typically 12-24+ months into therapy.

    Advanced Use Case 1: Maintenance After Weight Loss Goal Achievement

    Scenario: Target weight reached, transitioning to long-term maintenance.

    Protocol Options:

    Option A: Continued Full Dose Maintenance

    • Continue CagriSema 2.4 mg + 2.4 mg weekly
    • Rationale: strongest evidence for preventing regain
    • Drawback: ongoing cost and side effects

    Option B: Reduced Maintenance Dose

    • CagriSema 1.2 mg + 1.2 mg weekly (half dose)
    • Some clinical evidence for maintenance at lower doses
    • Balance: cost, convenience, prevention of regain

    Option C: Semaglutide Alone Maintenance

    • Discontinue cagrilintide, continue semaglutide 2.4 mg weekly
    • Rationale: leverage established GLP-1 monotherapy maintenance data
    • Concern: may see some regain vs dual therapy

    Option D: Gradual Discontinuation

    • Taper both drugs over 6-12 months
    • Intensive lifestyle reinforcement
    • Expect some regain (average ~50% of lost weight over 1-2 years post-discontinuation based on other weight-loss drug data)

    Advanced Use Case 2: Weight Regain After Discontinuation

    Scenario: Patient discontinued CagriSema, now regaining.

    Protocol:

    • Reassess readiness and realistic goals
    • Re-initiate CagriSema with titration (may be faster titration given prior exposure)
    • Lifestyle intervention intensification
    • Consider behavioral therapy
    • Address underlying factors (stress, sleep, medications)

    Advanced Use Case 3: Aggressive Weight Loss + Body Recomposition

    Scenario: Beyond standard weight loss — targeting specific body composition.

    Protocol:

    • CagriSema 2.4 mg + 2.4 mg weekly
    • Intensive resistance training (4-5x weekly)
    • Protein 2.0+ g/kg ideal body weight
    • Monitoring: DEXA every 3 months
    • Optional: GH peptides (Tesamorelin for visceral fat, CJC-1295/Ipamorelin for lean mass support)
    • HPG axis monitoring and support if needed
    • Medical oversight recommended

    Advanced Use Case 4: Diabetic Patient Optimization

    Scenario: Type 2 diabetes with obesity, seeking glycemic and weight control.

    Protocol:

    • CagriSema 2.4 mg + 2.4 mg weekly
    • Monitor HbA1c monthly during initiation
    • Reduce insulin/sulfonylurea doses proactively (hypoglycemia risk)
    • Coordinate with endocrinology
    • May be able to discontinue some diabetes medications
    • Target: HbA1c <7.0% and meaningful weight loss

    Advanced Use Case 5: Post-Bariatric Surgery Patient

    Scenario: Post-bariatric regain or inadequate response.

    Protocol:

    • CagriSema 2.4 mg + 2.4 mg weekly
    • Careful monitoring for GI effects (altered anatomy)
    • Adjust based on tolerance
    • Multivitamin/mineral supplementation (bariatric-appropriate)
    • Medical oversight essential
    • May need lower doses than non-bariatric patients

    Complex Monitoring for Advanced Protocols:

    • Quarterly comprehensive labs
    • DEXA every 3-6 months
    • Thyroid panel every 6 months
    • HPG axis every 6 months
    • Cardiovascular assessment annually
    • Mental health screening ongoing
    • Quality of life measures

    Integration with Multi-Peptide Protocols:

    With GH Axis:

    With Reproductive Axis:

    • Gonadorelin or HCG for men with rapid testosterone decline
    • Enclomiphene for long-term HPG maintenance
    • Reproductive endocrinology for women with amenorrhea

    With Repair/Recovery:

    • BPC-157, TB-500 for joint/tissue during increased activity
    • Thymosin-beta-4 family peptides
    • Timing: independent of CagriSema

    Long-Term Safety Surveillance:

    • Annual thyroid ultrasound if concerning history
    • Lifetime monitoring for pancreatitis signs
    • Gallbladder assessment if symptoms
    • Mental health vigilance
    • Cancer screening age-appropriate

    When to Consult Specialist:

    • Endocrinology: complex diabetes, thyroid abnormalities
    • Bariatric medicine: post-surgery or resistant cases
    • Cardiology: cardiovascular disease
    • Psychiatry: mental health concerns
    • Reproductive endocrinology: fertility issues
    • Oncology: concerning signs or findings

    Quality of Life Optimization:

    • Social eating strategies
    • Travel planning (refrigeration, time zones)
    • Stress management long-term
    • Partner/family involvement
    • Professional support (therapist, dietitian, trainer)

    Commonly Stacked With

    Cagrilintide is uniquely positioned as part of a designed combination (CagriSema) rather than a monotherapy, making stacking considerations substantially different from other peptides.

    Primary Stack: CagriSema (Cagrilintide + Semaglutide) This is the intended combination therapy:

    • Semaglutide 2.4 mg SC weekly
    • Cagrilintide 2.4 mg SC weekly (same injection day, can be same or different site)
    • Combined weight loss: 20-22% at 68 weeks
    • Mechanism: dual-axis anorexia (GLP-1 + amylin) without proportional GI increase

    Cagrilintide Monotherapy:

    • Possible at 4.5 mg weekly (Phase 2-established dose)
    • Weight loss: 10-11% at 26 weeks
    • Less common than CagriSema positioning; most commercial path emphasizes combination
    • Potentially useful in patients unable to tolerate GLP-1 agonists

    With Tirzepatide (Theoretical):

    • Hypothetical GLP-1/GIP + amylin combination
    • No clinical evidence; not commercially developed
    • Risk: unpredictable combined GI burden
    • Not recommended without clinical trial data

    With Retatrutide (Theoretical):

    • GLP-1/GIP/glucagon + amylin would be quadruple mechanism
    • Pre-clinical rationale possible
    • No human data
    • Likely too aggressive for initial development

    Lifestyle + CagriSema: The most evidence-based stack — CagriSema combined with:

    • Structured resistance training (preserves lean mass during weight loss)
    • Adequate protein intake (1.6-2.0 g/kg ideal body weight)
    • Caloric deficit nutritionally balanced
    • Monitoring body composition (DEXA) rather than just scale weight
    • Psychological support for eating behavior changes

    With Other Peptides:

    Growth Hormone Peptides for Lean Mass Preservation:

    • Sermorelin, CJC-1295 + Ipamorelin, Tesamorelin
    • Rationale: preserve lean mass during aggressive weight loss
    • Evidence: limited direct combination data
    • Consideration: timing (GH peptides in evening; cagrilintide any time weekly)

    Thyroid Support:

    • Not routinely indicated
    • Some rapid weight loss causes mild T3/T4 changes
    • Monitor TSH/free T4 every 3-6 months during aggressive weight loss
    • Adjust existing thyroid replacement if needed

    HPG Axis Preservation:

    • Rapid weight loss can suppress testosterone in men and menstrual cyclicity in women
    • Gonadorelin or Enclomiphene for men losing testosterone
    • Reproductive endocrinology consultation for women with amenorrhea

    Repair Peptides:

    • BPC-157, TB-500
    • No direct interaction with cagrilintide mechanism
    • May support joint/tissue health during weight loss and increased activity
    • Timing independent

    Immune Support:

    Avoid These Combinations:

    • Cagrilintide + pramlintide: same receptor target; redundant and potentially excessive
    • High-dose sulfonylureas or insulin without dose reduction: hypoglycemia risk (especially in diabetic patients)
    • Other weight-loss drugs without physician oversight: bupropion, phentermine, topiramate may produce unpredictable combined effects
    • Undisclosed research-grade supplementation without physician awareness

    Sequencing Strategies:

    • Ramp-up: start cagrilintide 0.3 mg weekly, titrate over 12-16 weeks to 2.4 mg
    • If on semaglutide: add cagrilintide 0.3 mg weekly, titrate as tolerated
    • If tirzepatide naive: CagriSema is the evidence-based combination; adding amylin to tirzepatide has no clinical data
    • Plateau management: if weight loss plateaus on semaglutide alone, adding cagrilintide (CagriSema) is evidence-based

    Monitoring Stack:

    • Weight: weekly during titration, monthly maintenance
    • Body composition: DEXA or impedance baseline and every 3-6 months
    • Lipid panel, HbA1c, liver enzymes baseline and every 3-6 months
    • Thyroid function baseline and annually
    • HPG axis (testosterone, menstrual cyclicity) as relevant

    Discontinuation Planning: Weight regain after discontinuation is well-documented for all weight-loss drugs. Strategies to minimize regain:

    • Gradual dose reduction rather than abrupt stop
    • Aggressive lifestyle reinforcement in final months
    • Maintenance lower-dose consideration (emerging practice)
    • Body composition monitoring to detect lean mass loss
    • Psychological support for behavioral maintenance

    Side Effects & Safety

    Cagrilintide's side-effect profile is dominated by gastrointestinal effects similar to but distinct from GLP-1 agonists, with some amylin-specific considerations. **Most Common Side Effects (from trials):** **Gastrointestinal (dose-dependent):** - **Nausea**: in the Phase 2 monotherapy trial, roughly 20%-47% across cagrilintide doses vs 18% placebo (overall GI adverse events 41%-63% vs 32% placebo) - generally mild-to-moderate, tends to decrease with continued dosing - **Vomiting**: more common at higher doses; less common than with GLP-1 agonists at equivalent weight loss - **Diarrhea**: moderate frequency - **Constipation**: less common than with semaglutide - **Decreased appetite**: expected and desired effect; can become problematic if excessive - **Dyspepsia / abdominal discomfort**: moderate frequency - **Early satiety**: expected effect, sometimes extreme **Metabolic Effects:** - **Fatigue**: modest, especially during rapid weight loss - **Headache**: mild-to-moderate, transient - **Dizziness**: especially in dehydrated individuals or with rapid dose escalation - **Injection site reactions**: mild, transient **CagriSema-Specific Considerations:** When combined with semaglutide, GI tolerability is broadly similar to semaglutide alone in the Phase 1b trial, suggesting the amylin component does not proportionally worsen GI adverse events despite adding a mechanism of action. In the larger Phase 3 REDEFINE trials, GI adverse events were common (about 72-80% with CagriSema vs 34-40% placebo) but mostly transient and mild-to-moderate. **Rare Serious Adverse Events:** - **Pancreatitis**: theoretical concern with incretin-amylin axis modulation; not clearly elevated in trials but monitoring required - **Gallbladder disease**: elevated risk during rapid weight loss (common with any weight-loss drug) - **Hypoglycemia**: rare with monotherapy in non-diabetic patients; more common when combined with insulin or sulfonylureas in diabetic patients **Amylin-Specific Considerations:** **Amyloidogenicity Concerns:** Native amylin is amyloidogenic and forms pancreatic amyloid in type 2 diabetes. Clinical amylin analogs (including cagrilintide) incorporate proline substitutions to prevent amyloid formation. Clinical trials to date have shown no evidence of iatrogenic amyloidosis from cagrilintide, but this remains a theoretical long-term consideration. **Calcitonin Receptor Effects:** Cagrilintide retains some calcitonin receptor binding, raising theoretical concerns about: - Thyroid C-cell effects (as with GLP-1 agonists) - Calcium/phosphate homeostasis (calcitonin's native role) Trials to date have not shown clinically meaningful effects in these domains. **Thyroid C-Cell Tumors:** Like GLP-1 agonists, cagrilintide carries a theoretical concern about medullary thyroid cancer risk based on rodent studies. CagriSema labeling will likely inherit the MTC/MEN2 contraindication from semaglutide. **Specific Populations:** **Pregnancy**: Like all weight-loss drugs, cagrilintide is not indicated during pregnancy. Weight loss is contraindicated during pregnancy. Women of reproductive potential should use effective contraception during treatment and discontinue before planned conception. **Elderly**: Limited data in patients >75 years; may require more careful dose titration given altered pharmacokinetics and increased fall risk with weight loss. **Renal Impairment**: Not primarily renally cleared, but caution warranted in severe renal impairment until more data accumulates. **Hepatic Impairment**: Limited data; exercise caution in severe hepatic dysfunction. **Children/Adolescents**: Not yet studied; pediatric obesity trials may follow adult approval. **Red Flags Requiring Discontinuation:** - Severe persistent nausea/vomiting unresponsive to supportive care - Signs of pancreatitis (severe abdominal pain radiating to back) - Signs of gallbladder disease (RUQ pain, jaundice) - Signs of hypoglycemia requiring rescue (especially in diabetic patients) - Psychiatric symptoms: significant mood changes - Severe injection site reactions - Any sign of thyroid abnormality (neck mass, dysphagia, dyspnea, hoarseness) **Long-Term Safety:** As a relatively new molecule (albeit with an amylin receptor mechanism dating to pramlintide's 2005 approval), cagrilintide lacks very long-term (5-10+ year) safety data. Post-marketing surveillance will be essential for: - Cancer signals (particularly thyroid) - Cardiovascular outcomes - Psychiatric effects - Weight regain trajectory after discontinuation - Effects on lean muscle mass **Comparison with Other Weight-Loss Drugs:** Cagrilintide (and by extension CagriSema) appears to have: - Similar overall GI tolerability to semaglutide (not proportionally worse despite dual mechanism) - Better than liraglutide for convenience (once weekly vs daily) - Less long-term data than liraglutide, semaglutide, or tirzepatide

    Contraindications

    **Absolute Contraindications:** - **Personal or family history of medullary thyroid carcinoma (MTC)** - **Multiple endocrine neoplasia type 2 (MEN2)** - **Known hypersensitivity** to cagrilintide, semaglutide, or any component - **Pregnancy** (weight loss contraindicated) - **Active eating disorder** (anorexia nervosa, severe bulimia) - **Severe untreated psychiatric conditions** **Relative Contraindications (Require Careful Evaluation):** - **History of pancreatitis**: not absolute but high caution - **Severe gastroparesis**: may worsen - **Gallbladder disease**: increased risk during rapid weight loss - **Inflammatory bowel disease**: caution with GI effects - **Severe renal impairment** (eGFR <30): limited data - **Severe hepatic impairment**: limited data - **Age >75**: careful titration needed - **Children/adolescents**: not yet studied **Drug Interactions:** **Medications Requiring Adjustment:** - **Insulin**: may need 20-40% dose reduction (hypoglycemia risk) - **Sulfonylureas**: consider dose reduction or discontinuation - **Thyroid replacement**: monitor and adjust as weight changes - **Levothyroxine**: absorption may be affected; separate by 30 min+ - **Oral contraceptives**: absorption may be altered; barrier backup recommended - **Warfarin**: monitor INR (altered absorption possible) **Medications to Use with Caution:** - **Other GLP-1 agonists**: avoid concurrent use (redundant, increased AE) - **Other amylin analogs** (pramlintide): avoid concurrent use - **Opioids**: may worsen constipation - **Sedatives**: may worsen dizziness - **Lithium**: altered clearance possible **Medications Compatible:** - Most antihypertensives - Statins - Metformin (often beneficial combination) - SSRIs (monitor mood changes) - Most thyroid medications (with monitoring) - Most HRT (estrogen, testosterone) **Medical Conditions Requiring Caution:** **Gastrointestinal:** - Gastroparesis: worsening risk - Inflammatory bowel disease: caution - Peptic ulcer disease: monitor - History of bowel obstruction: contraindicated **Pancreatic:** - History of pancreatitis: high caution - Pancreatic insufficiency: monitor - Pancreatic cancer risk: theoretical **Thyroid:** - Medullary thyroid carcinoma (personal or family): contraindicated - MEN2 syndrome: contraindicated - Benign thyroid nodules: monitor - Autoimmune thyroiditis: manage thyroid function separately **Gallbladder:** - Gallstones: increased risk with rapid weight loss - Previous cholecystectomy: no additional contraindication - Active symptoms: manage before starting **Cardiovascular:** - Recent myocardial infarction: delay start - Severe heart failure: monitor - Hypertension: typically improves with weight loss **Renal:** - Mild-moderate impairment: no major concerns - Severe impairment (eGFR <30): limited data - Hemodialysis: not well-studied **Hepatic:** - Non-alcoholic fatty liver: typically improves with weight loss - Severe cirrhosis: limited data - Alcoholic liver disease: manage separately **Psychiatric:** - Depression: monitor closely (any weight-loss drug can affect mood) - Anxiety disorders: monitor - History of suicidal ideation: careful monitoring - Eating disorders: contraindicated if active **Pregnancy/Reproductive:** - Pregnancy: absolute contraindication - Breastfeeding: not well-studied - Effective contraception during treatment - Pre-conception: discontinue 4-6 weeks before **When to Stop Immediately:** - Anaphylactoid/severe hypersensitivity reaction - Severe persistent pancreatitis symptoms - Suspected medullary thyroid cancer - Severe gallbladder disease - Severe psychiatric emergency - Pregnancy (discovery or planning) - Severe unexplained weight loss **When to Consult Physician:** - Severe or persistent GI symptoms - Suspected pancreatitis - New thyroid symptoms (neck mass, dysphagia) - Gallbladder symptoms - Significant mood changes - Severe fatigue - Unexpected labs - Pregnancy plans - New medical conditions **Pre-Treatment Assessment:** - Complete medical history - Medication reconciliation - Baseline labs (complete metabolic panel, lipids, HbA1c, TSH, liver enzymes) - Mental health screening - Physical exam - ECG if cardiovascular concerns - Pregnancy test if applicable - Patient education on risks/benefits **Monitoring Schedule:** - **Baseline**: complete evaluation - **Month 1**: clinical visit, symptoms review - **Month 3**: labs + clinical assessment - **Month 6**: labs + body composition + complete reassessment - **Month 12**: annual evaluation - **Ongoing**: symptom tracking, quality of life **Integration with Medical Care:** CagriSema/cagrilintide use benefits from clinical oversight: - Primary care with weight management expertise - Endocrinology for complex diabetes or thyroid - Bariatric medicine for advanced cases - Nutrition counseling - Mental health support Solo use is possible but coordination with physicians optimizes outcomes and safety. Insurance coverage often requires specific documentation and monitoring.

    Check interactions with the Interaction Checker →

    Additional Notes

    Standard Dose Ranges:

    Cagrilintide Monotherapy (Phase 2 established):

    • Initiation: 0.3 mg SC weekly
    • Titration: 0.6 1.2 2.4 4.5 mg weekly
    • Maintenance: 2.4-4.5 mg weekly
    • Increment interval: every 4 weeks

    CagriSema Combination (Phase 3 standard):

    • Semaglutide 2.4 mg + Cagrilintide 2.4 mg SC weekly
    • ~16-week co-escalation to full dose
    • Maintenance: ongoing weekly dosing

    Dose Escalation Rationale: The titration protocol is designed to minimize GI side effects. Most nausea and vomiting occurs during dose escalation phases. Slower titration may be warranted in:

    • Patients with severe initial GI response
    • Elderly patients
    • Patients with complex medical conditions

    Dose Reduction Strategies:

    • If intolerable nausea: reduce to previous tolerated dose for 4 more weeks, then re-escalate
    • If severe GI issues persist: consider switching to monotherapy (semaglutide or cagrilintide alone)
    • If weight loss excessive: reduce maintenance dose
    • If lean mass loss concerning: optimize protein/exercise first, then consider dose reduction

    Dose Dependence Relationships:

    Weight Loss vs Dose (cagrilintide monotherapy - Phase 2, Lau et al. 2021, 26 weeks):

    • Across the full 0.3-4.5 mg dose range, mean weight loss was 6.0%-10.8% vs 3.0% for placebo (the dose-response curve is relatively flat above ~1 mg)
    • 4.5 mg (highest dose): 10.8%, exceeding once-daily liraglutide 3.0 mg (9.0%)
    • Reference: Lau et al., 2021

    Side Effects vs Dose:

    • Higher doses: more nausea, vomiting
    • Typically manageable with titration
    • Most GI effects diminish with continued dosing

    Timing Considerations:

    Day of Week:

    • Any day works
    • Consistency matters more than specific day
    • Sunday or Monday common (align with weekly rhythm)
    • Avoid Friday/Saturday (GI effects during social eating)

    Time of Day:

    • Any time works (long half-life smooths effects)
    • Morning may be preferable for those with evening social eating
    • Consistency matters more than specific time

    Injection Site Rotation:

    • Abdomen (2+ inches from navel)
    • Thigh (outer)
    • Upper arm (back)
    • Rotate sites each injection
    • Record to avoid lipohypertrophy

    Source Quality:

    Pharmaceutical-Grade (Preferred):

    • Once FDA-approved, use commercial product
    • Clinical trial supply during trials
    • Compounded from licensed pharmacy (current off-label option)
    • USP-grade peptide verification

    Research-Grade (Lower Quality):

    • Grey-market sources
    • Variable purity
    • Storage concerns
    • Not recommended for therapeutic use

    Recognizing Quality:

    • Clear labeling
    • Expected concentration
    • Reputable source
    • Third-party COA
    • Proper storage during shipping

    Special Considerations:

    Concurrent Medications:

    • Insulin: may need 20-40% reduction
    • Sulfonylureas: consider discontinuation
    • Thyroid replacement: may need adjustment
    • Oral contraceptives: delayed absorption during rapid gastric emptying change
    • All prescriptions: inform physicians

    Pregnancy/Breastfeeding:

    • Not indicated during pregnancy
    • Discontinue before planned conception
    • Not studied during lactation
    • Effective contraception during treatment

    Elderly (>75):

    • Slower titration
    • Lower doses may be sufficient
    • Monitor for falls with weight loss
    • Assess cognitive status

    Pediatric:

    • Not yet studied
    • Pediatric trials may follow adult approval
    • Childhood obesity is increasing
    • Specific pediatric considerations will apply

    Renal Impairment:

    • Not primarily renally cleared
    • Monitor in severe renal disease
    • Adjust based on response and tolerance

    Hepatic Impairment:

    • Limited data
    • Caution in severe hepatic dysfunction
    • Monitor liver enzymes

    Surgical Considerations:

    • GLP-1 agonist component associated with retained gastric contents
    • Discontinue before surgery per anesthesia guidance
    • Coordinate with surgical team
    • Resume after recovery

    Cost Considerations:

    • Expected to be expensive (similar to other GLP-1 combination therapies)
    • Insurance coverage variable
    • Manufacturer programs may be available
    • Cost-benefit analysis for individual patients
    • Long-term investment in health

    Storage:

    • Refrigerate (2-8 deg C)
    • Do not freeze
    • Light protection preferred
    • Follow specific product instructions at approval

    Where to Buy Cagrilintide

    Compare 3 listings across 3 vendors — from $49.99

    Frequently Asked Questions

    What is the recommended Cagrilintide dosage?

    Dosage for Cagrilintide varies by protocol. Consult a qualified healthcare provider.

    How often should I take Cagrilintide?

    Once weekly

    Does Cagrilintide need to be cycled?

    Cycling requirements depend on the protocol. Follow established research guidelines.

    What are Cagrilintide side effects?

    Cagrilintide's side-effect profile is dominated by gastrointestinal effects similar to but distinct from GLP-1 agonists, with some amylin-specific considerations. **Most Common Side Effects (from trials):** **Gastrointestinal (dose-dependent):** - **Nausea**: in the Phase 2 monotherapy trial, roughly 20%-47% across cagrilintide doses vs 18% placebo (overall GI adverse events 41%-63% vs 32% placebo) - generally mild-to-moderate, tends to decrease with continued dosing - **Vomiting**: more common at higher doses; less common than with GLP-1 agonists at equivalent weight loss - **Diarrhea**: moderate frequency - **Constipation**: less common than with semaglutide - **Decreased appetite**: expected and desired effect; can become problematic if excessive - **Dyspepsia / abdominal discomfort**: moderate frequency - **Early satiety**: expected effect, sometimes extreme **Metabolic Effects:** - **Fatigue**: modest, especially during rapid weight loss - **Headache**: mild-to-moderate, transient - **Dizziness**: especially in dehydrated individuals or with rapid dose escalation - **Injection site reactions**: mild, transient **CagriSema-Specific Considerations:** When combined with semaglutide, GI tolerability is broadly similar to semaglutide alone in the Phase 1b trial, suggesting the amylin component does not proportionally worsen GI adverse events despite adding a mechanism of action. In the larger Phase 3 REDEFINE trials, GI adverse events were common (about 72-80% with CagriSema vs 34-40% placebo) but mostly transient and mild-to-moderate. **Rare Serious Adverse Events:** - **Pancreatitis**: theoretical concern with incretin-amylin axis modulation; not clearly elevated in trials but monitoring required - **Gallbladder disease**: elevated risk during rapid weight loss (common with any weight-loss drug) - **Hypoglycemia**: rare with monotherapy in non-diabetic patients; more common when combined with insulin or sulfonylureas in diabetic patients **Amylin-Specific Considerations:** **Amyloidogenicity Concerns:** Native amylin is amyloidogenic and forms pancreatic amyloid in type 2 diabetes. Clinical amylin analogs (including cagrilintide) incorporate proline substitutions to prevent amyloid formation. Clinical trials to date have shown no evidence of iatrogenic amyloidosis from cagrilintide, but this remains a theoretical long-term consideration. **Calcitonin Receptor Effects:** Cagrilintide retains some calcitonin receptor binding, raising theoretical concerns about: - Thyroid C-cell effects (as with GLP-1 agonists) - Calcium/phosphate homeostasis (calcitonin's native role) Trials to date have not shown clinically meaningful effects in these domains. **Thyroid C-Cell Tumors:** Like GLP-1 agonists, cagrilintide carries a theoretical concern about medullary thyroid cancer risk based on rodent studies. CagriSema labeling will likely inherit the MTC/MEN2 contraindication from semaglutide. **Specific Populations:** **Pregnancy**: Like all weight-loss drugs, cagrilintide is not indicated during pregnancy. Weight loss is contraindicated during pregnancy. Women of reproductive potential should use effective contraception during treatment and discontinue before planned conception. **Elderly**: Limited data in patients >75 years; may require more careful dose titration given altered pharmacokinetics and increased fall risk with weight loss. **Renal Impairment**: Not primarily renally cleared, but caution warranted in severe renal impairment until more data accumulates. **Hepatic Impairment**: Limited data; exercise caution in severe hepatic dysfunction. **Children/Adolescents**: Not yet studied; pediatric obesity trials may follow adult approval. **Red Flags Requiring Discontinuation:** - Severe persistent nausea/vomiting unresponsive to supportive care - Signs of pancreatitis (severe abdominal pain radiating to back) - Signs of gallbladder disease (RUQ pain, jaundice) - Signs of hypoglycemia requiring rescue (especially in diabetic patients) - Psychiatric symptoms: significant mood changes - Severe injection site reactions - Any sign of thyroid abnormality (neck mass, dysphagia, dyspnea, hoarseness) **Long-Term Safety:** As a relatively new molecule (albeit with an amylin receptor mechanism dating to pramlintide's 2005 approval), cagrilintide lacks very long-term (5-10+ year) safety data. Post-marketing surveillance will be essential for: - Cancer signals (particularly thyroid) - Cardiovascular outcomes - Psychiatric effects - Weight regain trajectory after discontinuation - Effects on lean muscle mass **Comparison with Other Weight-Loss Drugs:** Cagrilintide (and by extension CagriSema) appears to have: - Similar overall GI tolerability to semaglutide (not proportionally worse despite dual mechanism) - Better than liraglutide for convenience (once weekly vs daily) - Less long-term data than liraglutide, semaglutide, or tirzepatide

    Where can I buy Cagrilintide?

    Compare 3 listings from 3 vendors on our price comparison page — starting from $49.99.

    Free 2026 Peptide Cheat Sheet — 50 pages, PDF

    Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one.

    Download Free
    Shop BHG Labs · 20% off with BHG20